CMS Clarifies Rules for IDTF Medicare Billing of Diagnostic Tests
The agency recently issued new guidance exempting indirect independent diagnostic testing facilities from some requirements.
Already a member? Log in here
Labs Should Be Wary of Improper Billing of G0483 Testing
Recent OIG report says Medicare could have saved up to $215.8 million on at-risk payments for G0483 definitive drug tests.
Proposed Rule Puts Labs at Greater Risk of FCA Liability
CMS recently proposed a rule that would make the False Claims Act rule the standard for overpayments under the Affordable Care Act regulations.
Already a member? Log in here
OIG Sounds the Warning on Overbilling of G0483 Definitive Drug Tests
Labs may be billing Medicare for high-reimbursing and medically unnecessary drug tests, according to the OIG.
High Billing by Labs Continues to Be Trigger for Audits
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
Already a member? Log in here